Economic TimesLean R·
Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares rallied about 135% to $148.02 on Wednesday after its personalised mRNA cancer vaccine, developed with Merck, reduced the risk of melanoma recurrence and spread when combined with Keytruda in a late-stage trial, Reuters reported.The stock rose as high as $149.63 after closing the previous session at $62.96.Interim results from the ongoing study showed that the treatment, Intismeran, met its primary goal of reducing cancer recurrence and its secondary objective of preventing tumour…
Read at Economic Times →
